ADCIRCA® (tadalafil) Co-pay Assistance Program
ADCIRCA Co-Pay Assistance Card
For patients with commercial or private insurance plans, we offer a co-pay card to help patients cover some of their out-of-pocket expenses.
Eligible patients on commercial/private insurance plans may pay as little as a $5 co-pay per prescription filled (program covers the difference in co-pay above $5 up to $800 monthly).
Terms and Conditions
Important Safety Information for ADCIRCA® (tadalafil) tablets
CONTRAINDICATIONS
- Nitrates and Guanylate Cyclase (GC) Stimulators: Do not use ADCIRCA in patients taking medicines
that contain nitrates or guanylate cyclase stimulators (such as riociguat), as the combination could cause a sudden,
unsafe drop in blood pressure. Do not use nitrates within 48 hours of the last dose of ADCIRCA.
- Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil
should not take ADCIRCA
WARNINGS AND PRECAUTIONS
- Cardiovascular: Patients who experience anginal chest pain after taking ADCIRCA
should seek immediate medical attention
- Hypotension: Phosphodiesterase 5 inhibitors (PDE-5is), including tadalafil, have mild systemic
vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, carefully
consider whether patients with underlying cardiovascular disease could be adversely affected by such actions.
- Worsening Pulmonary Vascular Occlusive Disease: Pulmonary vasodilators may significantly worsen the
cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these
patients is not recommended
- Vision/Hearing: Patients who experience a sudden loss of vision in one or both eyes, which could
be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), or sudden decrease or loss of hearing after taking
ADCIRCA should seek immediate medical attention
- Prolonged Erection: In rare instances, men taking PDE-5is (including tadalafil) for ED reported
an erection lasting more than four hours. Male patients who experience a prolonged erection should seek immediate medical
attention
SPECIAL POPULATIONS AND POTENTIAL DRUG INTERACTIONS:
- Special Populations (Pregnant or Expecting Pregnancy): Limited data from case series with
tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse
maternal or fetal outcomes. Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure,
stroke, preterm delivery, and maternal and fetal death.
- Special Populations (Renal or Hepatic Impairment): The use of ADCIRCA is not recommended for
patients with severe renal or hepatic impairment. Please see Full Prescribing Information for dosing recommendations for
patients with mild to moderate renal or hepatic impairment
- Potential Drug Interactions: The use of ADCIRCA with alpha blockers, blood pressure medications,
or alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (light-headedness or fainting)
- Potential Drug Interactions: Tadalafil is metabolized predominately by CYP3A in the liver. Use of
ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA
therapy that require treatment with ritonavir, ADCIRCA should be discontinued at least 24 hours prior to starting ritonavir.
For patients on ritonavir therapy that require treatment with ADCIRCA, start ADCIRCA at 20 mg once a day. Use of ADCIRCA with
potent inducers of CYP3A, such as rifampin, should be avoided
- Potential Drug Interactions: ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is
used to treat erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH). The safety and
efficacy of combinations of ADCIRCA with Cialis or other PDE-5is have not been studied. Therefore, the use of such combinations
is not recommended
ADVERSE REACTIONS
- Adverse Reactions: The most common adverse event with ADCIRCA is headache (42% ADCIRCA
vs 15% placebo). Other common adverse events (reported by ≥9% of patients on ADCIRCA
and more frequent than placebo by 2%) include myalgia (14% vs 4%), nasopharyngitis
(13% vs 7%), flushing (13% vs 2%), respiratory tract infection (13% vs 6%), extremity
pain (11% vs 2%), nausea (11% vs 6%), back pain (10% vs 6%), dyspepsia (10% vs 2%),
and nasal congestion (9% vs 1%)
ADC.ISI.HCP.SEP2020
For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.
Reference: